Plasma CXCL9 elevations correlate with chronic GVHD diagnosis

Carrie L. Kitko, John E. Levine, Barry E. Storer, Xiaoyu Chai, David A. Fox, Thomas M. Braun, Daniel R. Couriel, Paul J. Martin, Mary E. Flowers, John A. Hansen, Lawrence Chang, Megan Conlon, Bryan J. Fiema, Rachel Morgan, Prae Pongtornpipat, Kelly Lamiman, James L M Ferrara, Stephanie J. Lee, Sophie Paczesny

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

There are no validated biomarkers for chronic GVHD (cGVHD). We used a protein microarray and subsequent sequential enzyme-linked immunosorbent assay to compare 17 patients with treatment-refractory de novo-onset cGVHD and 18 time-matched control patients without acute or chronicGVHDto identify 5 candidate proteins that distinguished cGVHD from no cGVHD: CXCL9, IL2Ra, elafin, CD13, and BAFF. We then assessed the discriminatory value of each protein individually and in composite panels in a validation cohort (n5109). CXCL9wasfoundtohavethehighest discriminatory valuewithanareaunder the receiver operating characteristic curve of 0.83 (95% confidence interval, 0.74-0.91).CXCL9 plasma concentrations above the median were associatedwith a higher frequency of cGVHD even after adjustment for other factors related todevelopingcGVHDincludingage, diagnosis, donor source, and degree of HLA matching (71% vs 20%; P > .001). A separate validation cohort from a different transplant center (n 5 211) confirmed that CXCL9 plasma concentrations abovethemedianwereassociatedwithmorefrequentnewlydiagnosedcGVHDafteradjustingfo r theaforementionedfactors (84% vs 60%; P 5 .001). Our results confirmthat CXCL9 is elevated in patients with newly diagnosed cGVHD.

Original languageEnglish
Pages (from-to)786-793
Number of pages8
JournalBlood
Volume123
Issue number5
DOIs
StatePublished - Jan 30 2014

Fingerprint

Plasmas
Elafin
Protein Array Analysis
Immunosorbents
Transplants
Proteins
Biomarkers
Microarrays
ROC Curve
Refractory materials
Assays
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Confidence Intervals
Composite materials
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kitko, C. L., Levine, J. E., Storer, B. E., Chai, X., Fox, D. A., Braun, T. M., ... Paczesny, S. (2014). Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 123(5), 786-793. https://doi.org/10.1182/blood-2013-08-520072

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. / Kitko, Carrie L.; Levine, John E.; Storer, Barry E.; Chai, Xiaoyu; Fox, David A.; Braun, Thomas M.; Couriel, Daniel R.; Martin, Paul J.; Flowers, Mary E.; Hansen, John A.; Chang, Lawrence; Conlon, Megan; Fiema, Bryan J.; Morgan, Rachel; Pongtornpipat, Prae; Lamiman, Kelly; Ferrara, James L M; Lee, Stephanie J.; Paczesny, Sophie.

In: Blood, Vol. 123, No. 5, 30.01.2014, p. 786-793.

Research output: Contribution to journalArticle

Kitko, CL, Levine, JE, Storer, BE, Chai, X, Fox, DA, Braun, TM, Couriel, DR, Martin, PJ, Flowers, ME, Hansen, JA, Chang, L, Conlon, M, Fiema, BJ, Morgan, R, Pongtornpipat, P, Lamiman, K, Ferrara, JLM, Lee, SJ & Paczesny, S 2014, 'Plasma CXCL9 elevations correlate with chronic GVHD diagnosis', Blood, vol. 123, no. 5, pp. 786-793. https://doi.org/10.1182/blood-2013-08-520072
Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014 Jan 30;123(5):786-793. https://doi.org/10.1182/blood-2013-08-520072
Kitko, Carrie L. ; Levine, John E. ; Storer, Barry E. ; Chai, Xiaoyu ; Fox, David A. ; Braun, Thomas M. ; Couriel, Daniel R. ; Martin, Paul J. ; Flowers, Mary E. ; Hansen, John A. ; Chang, Lawrence ; Conlon, Megan ; Fiema, Bryan J. ; Morgan, Rachel ; Pongtornpipat, Prae ; Lamiman, Kelly ; Ferrara, James L M ; Lee, Stephanie J. ; Paczesny, Sophie. / Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. In: Blood. 2014 ; Vol. 123, No. 5. pp. 786-793.
@article{210ce5bf8b724e46886c014741b6b2f5,
title = "Plasma CXCL9 elevations correlate with chronic GVHD diagnosis",
abstract = "There are no validated biomarkers for chronic GVHD (cGVHD). We used a protein microarray and subsequent sequential enzyme-linked immunosorbent assay to compare 17 patients with treatment-refractory de novo-onset cGVHD and 18 time-matched control patients without acute or chronicGVHDto identify 5 candidate proteins that distinguished cGVHD from no cGVHD: CXCL9, IL2Ra, elafin, CD13, and BAFF. We then assessed the discriminatory value of each protein individually and in composite panels in a validation cohort (n5109). CXCL9wasfoundtohavethehighest discriminatory valuewithanareaunder the receiver operating characteristic curve of 0.83 (95{\%} confidence interval, 0.74-0.91).CXCL9 plasma concentrations above the median were associatedwith a higher frequency of cGVHD even after adjustment for other factors related todevelopingcGVHDincludingage, diagnosis, donor source, and degree of HLA matching (71{\%} vs 20{\%}; P > .001). A separate validation cohort from a different transplant center (n 5 211) confirmed that CXCL9 plasma concentrations abovethemedianwereassociatedwithmorefrequentnewlydiagnosedcGVHDafteradjustingfo r theaforementionedfactors (84{\%} vs 60{\%}; P 5 .001). Our results confirmthat CXCL9 is elevated in patients with newly diagnosed cGVHD.",
author = "Kitko, {Carrie L.} and Levine, {John E.} and Storer, {Barry E.} and Xiaoyu Chai and Fox, {David A.} and Braun, {Thomas M.} and Couriel, {Daniel R.} and Martin, {Paul J.} and Flowers, {Mary E.} and Hansen, {John A.} and Lawrence Chang and Megan Conlon and Fiema, {Bryan J.} and Rachel Morgan and Prae Pongtornpipat and Kelly Lamiman and Ferrara, {James L M} and Lee, {Stephanie J.} and Sophie Paczesny",
year = "2014",
month = "1",
day = "30",
doi = "10.1182/blood-2013-08-520072",
language = "English",
volume = "123",
pages = "786--793",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Plasma CXCL9 elevations correlate with chronic GVHD diagnosis

AU - Kitko, Carrie L.

AU - Levine, John E.

AU - Storer, Barry E.

AU - Chai, Xiaoyu

AU - Fox, David A.

AU - Braun, Thomas M.

AU - Couriel, Daniel R.

AU - Martin, Paul J.

AU - Flowers, Mary E.

AU - Hansen, John A.

AU - Chang, Lawrence

AU - Conlon, Megan

AU - Fiema, Bryan J.

AU - Morgan, Rachel

AU - Pongtornpipat, Prae

AU - Lamiman, Kelly

AU - Ferrara, James L M

AU - Lee, Stephanie J.

AU - Paczesny, Sophie

PY - 2014/1/30

Y1 - 2014/1/30

N2 - There are no validated biomarkers for chronic GVHD (cGVHD). We used a protein microarray and subsequent sequential enzyme-linked immunosorbent assay to compare 17 patients with treatment-refractory de novo-onset cGVHD and 18 time-matched control patients without acute or chronicGVHDto identify 5 candidate proteins that distinguished cGVHD from no cGVHD: CXCL9, IL2Ra, elafin, CD13, and BAFF. We then assessed the discriminatory value of each protein individually and in composite panels in a validation cohort (n5109). CXCL9wasfoundtohavethehighest discriminatory valuewithanareaunder the receiver operating characteristic curve of 0.83 (95% confidence interval, 0.74-0.91).CXCL9 plasma concentrations above the median were associatedwith a higher frequency of cGVHD even after adjustment for other factors related todevelopingcGVHDincludingage, diagnosis, donor source, and degree of HLA matching (71% vs 20%; P > .001). A separate validation cohort from a different transplant center (n 5 211) confirmed that CXCL9 plasma concentrations abovethemedianwereassociatedwithmorefrequentnewlydiagnosedcGVHDafteradjustingfo r theaforementionedfactors (84% vs 60%; P 5 .001). Our results confirmthat CXCL9 is elevated in patients with newly diagnosed cGVHD.

AB - There are no validated biomarkers for chronic GVHD (cGVHD). We used a protein microarray and subsequent sequential enzyme-linked immunosorbent assay to compare 17 patients with treatment-refractory de novo-onset cGVHD and 18 time-matched control patients without acute or chronicGVHDto identify 5 candidate proteins that distinguished cGVHD from no cGVHD: CXCL9, IL2Ra, elafin, CD13, and BAFF. We then assessed the discriminatory value of each protein individually and in composite panels in a validation cohort (n5109). CXCL9wasfoundtohavethehighest discriminatory valuewithanareaunder the receiver operating characteristic curve of 0.83 (95% confidence interval, 0.74-0.91).CXCL9 plasma concentrations above the median were associatedwith a higher frequency of cGVHD even after adjustment for other factors related todevelopingcGVHDincludingage, diagnosis, donor source, and degree of HLA matching (71% vs 20%; P > .001). A separate validation cohort from a different transplant center (n 5 211) confirmed that CXCL9 plasma concentrations abovethemedianwereassociatedwithmorefrequentnewlydiagnosedcGVHDafteradjustingfo r theaforementionedfactors (84% vs 60%; P 5 .001). Our results confirmthat CXCL9 is elevated in patients with newly diagnosed cGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84894035968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894035968&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-08-520072

DO - 10.1182/blood-2013-08-520072

M3 - Article

C2 - 24363401

AN - SCOPUS:84894035968

VL - 123

SP - 786

EP - 793

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -